Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pertuzumab biosimilar - Qilu pharmaceutical

Next Previous
Drug Profile

Pertuzumab biosimilar - Qilu pharmaceutical

Alternative Names: QL-1209

Latest Information Update: 26 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qilu Pharmaceutical
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer

Most Recent Events

  • 23 Sep 2025 Shandong Cancer Hospital and Institute plans a clinical trial for HER2-positive breast cancer (Neoadjuvant therapy, Combination therapy) in Unknown location (Parenteral) in September 2025 (NCT07187752)
  • 19 Mar 2025 Qilu Pharmaceutical plans a phase I trial for Solid tumours (Late stage disease, Metastatic disease, Second line therapy or greater) in April 2025 (NCT06872580)
  • 28 Dec 2023 No recent reports of development identified for phase-I development in Breast-cancer(In volunteers) in China (IV, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top